Mirtazapine Teva (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and antagonizes postsynaptic 5‑HT2 and 5‑HT3 receptors, enhancing serotonergic activity. Its strong H1 histamine antagonism also contributes to sedation and appetite stimulation.

The appropriate dose of Mirtazapine Teva is determined by the prescribing clinician based on the patient’s condition, response, and tolerability. Dosage adjustments are made individually, and patients should follow the prescriber’s instructions.

Safety data for mirtazapine in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine has a distinct receptor profile that often results in greater sedation and appetite stimulation, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about weight gain.

Mirtazapine Teva tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Mirtazapine Teva is taken orally, usually once daily in the evening due to its sedative effect. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis, severe hepatic dysfunction, and the emergence or worsening of suicidal thoughts, especially during the early phase of treatment. Patients should be monitored closely for any signs of infection, liver issues, or changes in mood.

Mirtazapine should be avoided in patients who have taken monoamine oxidase inhibitors within the past 14 days, those with known hypersensitivity to the drug, or individuals with severe hepatic impairment without appropriate dose adjustment.